Maximus earnings beat by $0.15, revenue topped estimates

Maximus reported Q4 EPS of $1.62 versus the $1.47 consensus and revenue of $1.32 billion versus $1.31 billion, and guided FY2026 EPS to $7.95–$8.25 versus a $7.45 consensus while forecasting revenue of $5.23–$5.43 billion versus a $5.45 billion consensus. The results point to a beat on profitability and a slightly cautious top‑line outlook, suggesting margin strength but softer revenue growth than analysts expected. The stock closed at $77.76 (down ~10.6% over three months), and the company has seen two positive EPS revisions in the past 90 days, indicating improving earnings momentum despite mixed guidance.

Analysis

Maximus reported fourth-quarter EPS of $1.62 versus the $1.47 consensus and revenue of $1.32 billion versus $1.31 billion, signaling a clear upside to profitability and a marginal top-line beat for the quarter. The EPS beat of $0.15 and the narrow revenue outperformance point to operational leverage or margin improvement driving the beat rather than meaningful acceleration in sales.

Management guided FY2026 EPS to $7.95–$8.25 versus a $7.45 analyst consensus while projecting revenue of $5.23–$5.43 billion against a $5.45 billion consensus, implying management expects continued margin strength but a slightly more conservative revenue outlook. The divergence—higher EPS guide with slightly lower revenue guidance—suggests cost control or mix improvement is expected to expand margins, but it increases execution risk if revenue trends soften.

The stock closed at $77.76, is down 10.62% over three months and up 3.74% over 12 months, and has seen two positive EPS revisions in the last 90 days with a Financial Health score of "good performance," consistent with the mildly positive sentiment metric. Investors should watch near-term revenue trajectory and subsequent analyst revisions as the primary catalysts that will validate the margin-driven thesis or expose downside to consensus expectations.

Key Decisions for Investors

• Consider a modest add or overweight if you have a margin-focused thesis because management raised FY26 EPS guidance above consensus, size positions conservatively
• Delay any significant position increases until upcoming quarters confirm revenue growth given guidance range sits slightly below consensus, monitor sales cadence closely
• Track analyst revisions and the next quarterly results as key catalysts; tighten stops or hedge if EPS revisions stall or revenue trends deteriorate